Christoph U. Correll, MD
a:3:{i:0;s:71:"Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York";i:1;s:135:"Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York";i:2;s:93:"Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany";}
Academic Highlights
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
June 13, 2025
A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.
Insights
What are the Efficacy and Safety of Muscarinic Receptor Modulators in Patients With Schizophrenia?
November 19, 2024
In this video, Dr. Correll examines the therapeutic potential of the muscarinic receptor system in schizophrenia treatment. He discusses how targeting muscarinic receptors may address cognitive and functional impairments,...
Insights
What is the Place of Muscarinic Receptor Modulators in the Clinical Care of Patients With Schizophrenia?
November 19, 2024
This video features Dr. Christoph Correll discussing the clinical application of muscarinic receptor modulators in schizophrenia treatment. He explores their unique mechanism of action, compares them to traditional antipsychotics,...
Narrative Review
Alternative Treatment for Agitation in Schizophrenia and Bipolar Disorder
January 30, 2024
While oral and intramuscular formulations of pharmacologic agents continue to be commonly used to treat acute agitation, novel agents with alternative routes of delivery are becoming available.
